Skip to content
Screener

Stock-Based Comp at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$38M+26.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$458M+11.7%
Staar Surgical logo
Staar SurgicalSTAA
$4.82M-19.8%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$312K-30.8%
Ardelyx logo
ArdelyxARDX
$15.32M+31.1%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$3.24M-28.5%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$2.21B+3.8%
Enterprise value$21.66B-2.1%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 6:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885590-26-000053
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net gain on sale of assets(3)
Adjustments to accrued legal settlements10(3)
Payments of accrued legal settlements(161)(19)
Share-based compensation5243
Gain excluded from hedge effectiveness(3)(3)
Loss on extinguishment of debt1
Payments of contingent consideration adjustments, including accretion(3)(2)
Amortization of inventory step-up resulting from acquisitions322

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch Health Companies's stock-based comp?
Bausch Health Companies (BHC) reported stock-based comp of $52M in Q1 2026.
How has Bausch Health Companies's stock-based comp changed year-over-year?
Bausch Health Companies's stock-based comp increased by 20.9% year-over-year, from $43M to $52M.
What is the long-term trend for Bausch Health Companies's stock-based comp?
Over 4 years (2021 to 2025), Bausch Health Companies's stock-based comp has grown at a 14.0% compound annual growth rate (CAGR), from $128M to $216M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Bausch Health Companies's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude